{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:49:18Z","timestamp":1781196558833,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40262-025-01512-5","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T07:56:41Z","timestamp":1751270201000},"page":"1341-1355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Population Pharmacokinetics and Pharmacodynamics Modeling for the Use of Recaticimab in Healthy Volunteers and Patients with Hypercholesterolemia"],"prefix":"10.1007","volume":"64","clinical-trial-number":[{"clinical-trial-number":"nct03634436","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03944109","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05370950","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04455581","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04849000","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04885218","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04844125","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Chang","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0439-635X","authenticated-orcid":false,"given":"Kai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"1512_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.arcmed.2015.06.006","volume":"46","author":"S Barquera","year":"2015","unstructured":"Barquera S, Pedroza-Tob\u00edas A, Medina C, Hern\u00e1ndez-Barrera L, Bibbins-Domingo K, Lozano R, Moran AE. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res. 2015;46:328\u201338. https:\/\/doi.org\/10.1016\/j.arcmed.2015.06.006.","journal-title":"Arch Med Res"},{"key":"1512_CR2","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fern\u00e1ndez-Sol\u00e0 J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundstr\u00f6m J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982\u20133021. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010.","journal-title":"J Am Coll Cardiol"},{"key":"1512_CR3","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/s0140-6736(06)69292-1","volume":"368","author":"P Deedwania","year":"2006","unstructured":"Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to new targets study. Lancet. 2006;368:919\u201328. https:\/\/doi.org\/10.1016\/s0140-6736(06)69292-1.","journal-title":"Lancet"},{"key":"1512_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"1512_CR5","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of cardiology\/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2889\u2013934. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.002.","journal-title":"J Am Coll Cardiol"},{"key":"1512_CR6","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","volume":"8","author":"JR Guyton","year":"2014","unstructured":"Guyton JR, Bays HE, Grundy SM, Jacobson TA. Panel. TNLASI. An assessment by the statin intolerance panel: 2014 update. J Clin Lipidol. 2014;8:S72-81. https:\/\/doi.org\/10.1016\/j.jacl.2014.03.002.","journal-title":"J Clin Lipidol"},{"key":"1512_CR7","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.0044","volume":"8","author":"RS Rosenson","year":"2014","unstructured":"Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association\u2019s Muscle Safety Expert P. An assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8:S58-71. https:\/\/doi.org\/10.1016\/j.jacl.2014.03.0044.","journal-title":"J Clin Lipidol"},{"key":"1512_CR8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","volume":"49","author":"HE Careskey","year":"2008","unstructured":"Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9. J Lipid Res. 2008;49:394\u20138. https:\/\/doi.org\/10.1194\/jlr.M700437-JLR200.","journal-title":"J Lipid Res"},{"key":"1512_CR9","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1161\/01.atv.0000134621.14315.43","volume":"24","author":"G Dubuc","year":"2004","unstructured":"Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004;24:1454\u20139. https:\/\/doi.org\/10.1161\/01.atv.0000134621.14315.43.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1512_CR10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1073\/pnas.0335507100","volume":"100","author":"NG Seidah","year":"2003","unstructured":"Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003;100:928\u201333. https:\/\/doi.org\/10.1073\/pnas.0335507100.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1512_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/hep.22354","volume":"48","author":"A Zaid","year":"2008","unstructured":"Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A. Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008;48:646\u201354. https:\/\/doi.org\/10.1002\/hep.22354.","journal-title":"Hepatology"},{"key":"1512_CR12","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","volume":"62","author":"D Urban","year":"2013","unstructured":"Urban D, P\u00f6ss J, B\u00f6hm M, Laufs U. Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013;62:1401\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2013.07.056.","journal-title":"J Am Coll Cardiol"},{"key":"1512_CR13","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/embor.2011.205","volume":"12","author":"P Lo Surdo","year":"2011","unstructured":"Lo Surdo P, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A, Carf\u00ed A. Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH. EMBO Rep. 2011;12:1300\u20135. https:\/\/doi.org\/10.1038\/embor.2011.205.","journal-title":"EMBO Rep"},{"key":"1512_CR14","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/hmg\/ddr578","volume":"21","author":"K Tveten","year":"2012","unstructured":"Tveten K, Holla \u00d8L, Cameron J, Str\u00f8m TB, Berge KE, Laerdahl JK, Leren TP. Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification. Hum Mol Genet. 2012;21:1402\u20139. https:\/\/doi.org\/10.1093\/hmg\/ddr578.","journal-title":"Hum Mol Genet"},{"key":"1512_CR15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jacl.2015.01.001","volume":"9","author":"JM McKenney","year":"2015","unstructured":"McKenney JM. Understanding PCSK9 and anti-PCSK9 therapies. J Clin Lipidol. 2015;9:170\u201386. https:\/\/doi.org\/10.1016\/j.jacl.2015.01.001.","journal-title":"J Clin Lipidol"},{"key":"1512_CR16","unstructured":"Joint Committee on the Chinese Guidelines for Lipid M. Chinese guidelines for lipid management (2023). Zhonghua Xin Xue Guan Bing Za Zhi 2023;51:221\u201355."},{"key":"1512_CR17","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/cir.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. Circulation. 2019;139:e1082\u2013143. https:\/\/doi.org\/10.1161\/cir.0000000000000625.","journal-title":"Circulation"},{"key":"1512_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12916-021-02208-w","volume":"20","author":"M Xu","year":"2022","unstructured":"Xu M, Zhu X, Wu J, Zhang Y, Zhao D, Wang X, Ding Y, Cao Y, Li C, Hu W, Sheng J, Luo Z, Zheng Z, Hu J, Liu J, Zhou X, Shen A, Ding X, Zhang Y, Zhao Y, Li Y, Zhong S, An S, Zou J, Yan L. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b\/2 study. BMC Med. 2022;20:13. https:\/\/doi.org\/10.1186\/s12916-021-02208-w.","journal-title":"BMC Med"},{"key":"1512_CR19","unstructured":"ESC. Recaticimab monotherapy in patients with non-familial hypercholesterolaemia and mixed hyperlipaemia (REMAIN-1): a multicentre, randomised, double-blind, placebo-controlled phase 3 study. In: Presented at late-breaking science session. ESC; 2023."},{"key":"1512_CR20","unstructured":"AHA. Recaticimab add-on therapy in patients with non-familial hypercholesterolaemia and mixed hyperlipidemia (REMAIN-2): a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. In: Presented at late-breaking science session. AHA; 2023."},{"key":"1512_CR21","unstructured":"Sanofi. PRALUENT\u2122 (alirocumab) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125559s002lbl.pdf. Accessed 9 Jan 2024."},{"key":"1512_CR22","unstructured":"Amgen. REPATHA\u2122 (evolocumab) U.S. prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125522s014lbl.pdf. Accessed 9 Jan 2024."},{"key":"1512_CR23","unstructured":"The PK\/PD Study of a Single Subcutaneous Injection of SHR-1209 in Healthy Subjects (NCT03634436). https:\/\/www.clinicaltrials.gov\/study\/NCT03634436. Accessed 23 Aug 2024."},{"key":"1512_CR24","unstructured":"The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia (NCT03944109). https:\/\/www.clinicaltrials.gov\/study\/NCT03944109. Accessed 23 Aug 2024."},{"key":"1512_CR25","unstructured":"Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers (NCT05370950). https:\/\/www.clinicaltrials.gov\/study\/NCT05370950. Accessed 23 Aug 2024."},{"key":"1512_CR26","unstructured":"A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia (NCT04455581). https:\/\/www.clinicaltrials.gov\/study\/NCT04455581. Accessed 23 Aug 2024."},{"key":"1512_CR27","unstructured":"Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia III Stage (NCT04849000). https:\/\/www.clinicaltrials.gov\/study\/NCT04849000. Accessed 23 Aug 2024."},{"key":"1512_CR28","unstructured":"Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia (NCT04885218). https:\/\/www.clinicaltrials.gov\/study\/NCT04885218. Accessed 23 Aug 2024."},{"key":"1512_CR29","unstructured":"SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia III Period Clinical Research (NCT04844125). https:\/\/www.clinicaltrials.gov\/study\/NCT04844125. Accessed 23 Aug 2024."},{"key":"1512_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1023\/a:1014414520282","volume":"28","author":"DE Mager","year":"2001","unstructured":"Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507\u201332. https:\/\/doi.org\/10.1023\/a:1014414520282.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1512_CR31","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40262-016-0505-1","volume":"56","author":"N Djebli","year":"2017","unstructured":"Djebli N, Martinez JM, Lohan L, Khier S, Brunet A, Hurbin F, Fabre D. Target-mediated drug disposition population pharmacokinetics model of alirocumab in healthy volunteers and patients: pooled analysis of randomized phase I\/II\/III studies. Clin Pharmacokinet. 2017;56:1155\u201371. https:\/\/doi.org\/10.1007\/s40262-016-0505-1.","journal-title":"Clin Pharmacokinet"},{"key":"1512_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40262-018-0670-5","volume":"58","author":"X Nicolas","year":"2019","unstructured":"Nicolas X, Djebli N, Rauch C, Brunet A, Hurbin F, Martinez JM, Fabre D. Population pharmacokinetic\/pharmacodynamic analysis of alirocumab in healthy volunteers or hypercholesterolemic subjects using an indirect response model to predict low-density lipoprotein cholesterol lowering: support for a biologics license application submission: part II. Clin Pharmacokinet. 2019;58:115\u201330. https:\/\/doi.org\/10.1007\/s40262-018-0670-5.","journal-title":"Clin Pharmacokinet"},{"key":"1512_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10928-008-9102-8","volume":"35","author":"L Gibiansky","year":"2008","unstructured":"Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008;35:573\u201391. https:\/\/doi.org\/10.1007\/s10928-008-9102-8.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1512_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1476-511x-7-22","volume":"7","author":"J Mayne","year":"2008","unstructured":"Mayne J, Dewpura T, Raymond A, Cousins M, Chaplin A, Lahey KA, Lahaye SA, Mbikay M, Ooi TC, Chr\u00e9tien M. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis. 2008;7:22. https:\/\/doi.org\/10.1186\/1476-511x-7-22.","journal-title":"Lipids Health Dis"},{"key":"1512_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cca.2014.07.008","volume":"437","author":"YL Guo","year":"2014","unstructured":"Guo YL, Zhang W, Li JJ. PCSK9 and lipid lowering drugs. Clin Chim Acta. 2014;437:66\u201371. https:\/\/doi.org\/10.1016\/j.cca.2014.07.008.","journal-title":"Clin Chim Acta"},{"key":"1512_CR36","doi-asserted-by":"publisher","first-page":"50630","DOI":"10.1074\/jbc.M410077200","volume":"279","author":"SW Park","year":"2004","unstructured":"Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver. J Biol Chem. 2004;279:50630\u20138. https:\/\/doi.org\/10.1074\/jbc.M410077200.","journal-title":"J Biol Chem"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01512-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01512-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01512-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:12:53Z","timestamp":1757466773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01512-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1512"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01512-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"17 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jiangsu Hengrui Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Chang S, Ying W, Sheng F, Shengxian Y, Kai S were all employed by Jiangsu Hengrui Pharmaceuticals. All authors declare that there are no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Informed consent was obtained from all individual participants included in the studies. No identifying information for individual patients is included in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not available.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not available.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The individual patient data generated during this study will be considered for sharing after the product and indications have been approved by major health authorities. The data may be requested 24 months after study completion. Qualified researchers should submit a proposal to the corresponding author outlining the reasons for the data request. The sponsor will provide the data if the proposal is approved, provided that the requestor signs a data-access agreement. The use of data must comply with the requirements of the Human Genetics Resources Administration of China and other country- or region-specific regulations.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not available.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Chang S was responsible for drafting the analysis plan, verifying the dataset, conducting modeling and analysis, and drafting the manuscript. Ying W was in charge of clinical pharmacology of recaticimab and was accountable for materials collection; Shengxian Y programmed the dataset; the project was under supervised by Sheng F and Kai S.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}